Ignite Creation Date:
2025-12-25 @ 5:04 AM
Ignite Modification Date:
2025-12-26 @ 4:06 AM
Study NCT ID:
NCT06104618
Status:
RECRUITING
Last Update Posted:
2025-12-11
First Post:
2023-10-23
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D010412', 'term': 'Penile Neoplasms'}], 'ancestors': [{'id': 'D005834', 'term': 'Genital Neoplasms, Male'}, {'id': 'D014565', 'term': 'Urogenital Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D005832', 'term': 'Genital Diseases, Male'}, {'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D010409', 'term': 'Penile Diseases'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000632577', 'term': 'enfortumab vedotin'}, {'id': 'D009682', 'term': 'Magnetic Resonance Spectroscopy'}], 'ancestors': [{'id': 'D013057', 'term': 'Spectrum Analysis'}, {'id': 'D002623', 'term': 'Chemistry Techniques, Analytical'}, {'id': 'D008919', 'term': 'Investigative Techniques'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 28}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2023-12-21', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-12', 'completionDateStruct': {'date': '2026-11-01', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-12-09', 'studyFirstSubmitDate': '2023-10-23', 'studyFirstSubmitQcDate': '2023-10-23', 'lastUpdatePostDateStruct': {'date': '2025-12-11', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2023-10-27', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-11-01', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Best response rate', 'timeFrame': 'Up to 5 years', 'description': 'Defined as the proportion of patients who experience either a partial response (PR) or complete response (CR) as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. The best response rate of CR/PR will be reported descriptively and a 95% confidence interval will be reported.'}], 'secondaryOutcomes': [{'measure': 'Objective response rate (ORR)', 'timeFrame': 'Up to 5 years', 'description': 'Defined as the proportion of patients who experience either a confirmed partial response or confirmed complete response as defined by RECIST v1.1. ORR will be reported descriptively and a 95% confidence interval will be reported.'}, {'measure': 'Progression free survival (PFS)', 'timeFrame': 'From study entry to the first of either disease progression or death from any cause, up to 5 years', 'description': 'Will be estimated using the Kaplan-Meier method. The median PFS and 95% confidence interval will be reported.'}, {'measure': 'Overall survival (OS)', 'timeFrame': 'From study entry to death from any cause, up to 5 years', 'description': 'Will be estimated using the Kaplan-Meier method. The median OS and 95% confidence interval will be reported.'}, {'measure': 'Incidence of adverse events', 'timeFrame': 'Up to 30 days after last dose of study medication', 'description': 'The maximum grade for each type of adverse event by patient will be summarized by frequencies and percentages using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.'}, {'measure': 'Duration of Response', 'timeFrame': 'Up to 5 years', 'description': "Defined for all evaluable patients who have achieved an objective response as the date at which the patient's earliest best objective status is first noted to be either a CR or PR to the earliest date progression is documented."}, {'measure': 'Best response by human papillomavirus (HPV) status', 'timeFrame': 'Up to 5 years', 'description': 'The p16 biomarker will be used to assess HPV status. The p16 immunohistochemistry (IHC) outcome will be classified as positive, negative, or not available. Best response rates of either a CR or PR will be determined for each subgroup and 95% confidence intervals will be reported.'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Metastatic Penile Squamous Cell Carcinoma', 'Stage III Penile Cancer AJCC v8', 'Stage IV Penile Cancer AJCC v8', 'Unresectable Penile Squamous Cell Carcinoma']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'https://www.mayo.edu/research/clinical-trials', 'label': 'Mayo Clinic Clinical Trials'}]}, 'descriptionModule': {'briefSummary': 'This phase II trial tests how well enfortumab vedotin works for treating patients with squamous cell carcinoma of the penis that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Enfortumab vedotin is a monoclonal antibody, enfortumab, linked to an anticancer drug called vedotin. It works by helping the immune system to slow or stop the growth of tumor cells. Enfortumab attaches to a protein called nectin-4 on tumor cells in a targeted way and delivers vedotin to kill them.', 'detailedDescription': 'PRIMARY OBJECTIVE:\n\nI. To estimate the best response rate of enfortumab vedotin treatment for patients with metastatic penile squamous cell carcinoma (mPSCC).\n\nSECONDARY OBJECTIVES:\n\nI. To determine overall response rate (ORR). II. To determine safety and tolerance of enfortumab vedotin in men with mPSCC. III. To characterize duration of response to enfortumab vedotin in mPSCC. IV. To estimate median overall survival and progression-free survival in men with mPSCC treated with enfortumab vedotin.\n\nV. To analyze response in subgroups by human papillomavirus (HPV) status (related/unrelated as assessed by p16 biomarker).\n\nOUTLINE:\n\nPatients receive enfortumab vedotin intravenously (IV) over 30 minutes on days 1,8 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT) or magnetic resonance imaging (MRI) throughout the study.\n\nAfter completion of study treatment, patients are followed up at 30 days and then every 3 months until progressive disease, followed by every 6 months for up to 5 years from registration.'}, 'eligibilityModule': {'sex': 'MALE', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Age ≥ 18 years\n* Histological confirmation of squamous cell carcinoma of the penis (PSCC): NOTE: Biopsy confirmation of at least one site of metastasis is encouraged but not required.\n* At least one site of metastatic or unresectable PSCC. NOTE: Prior therapy is not required for patients whose treatment is considered palliative (for example, presence of distant metastasis). NOTE: Patients who are potentially curable (any T, N1 - N3, M0) must have had tumor progression after standard chemotherapy, radiotherapy, or surgery, or be unable to receive such treatment. Eligible stages include:\n\n * Any T, N1 (i.e., a palpable mobile unilateral inguinal lymph node), M0 OR\n * Any T, N2 (i.e., palpable mobile multiple or bilateral inguinal lymph nodes), M0 OR\n * Any T, N3 (i.e., fixed inguinal nodal mass or any pelvic lymphadenopathy), M0 OR\n * Any T, any N, M1\n* Patients with clinical N1, M0 mPSCC at protocol entry must be ineligible for surgery because of comorbidities or clinical T4 disease, or have refused surgery\n* Patients with clinical N1 - N3, M0, and no prior systemic therapy must be:\n\n * Unable to receive neoadjuvant (paclitaxel + ifosfamide + cisplatin) TIP because of comorbidities or refused TIP; AND\n * Unable to receive radiotherapy with curative intent, or refused radiotherapy\n* Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST 1.1)\n* Prior therapy is allowed. Patients may be treatment-naïve or have had any number of prior anti-cancer treatments\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1\n* Hemoglobin ≥ 9.0 g/dL obtained ≤15 days prior to registration\n* Absolute neutrophil count (ANC) ≥ 1000/mm\\^3 obtained ≤ 15 days prior to registration\n* Platelet count ≥ 100,000/mm\\^3 obtained ≤ 15 days prior to registration\n* Total bilirubin ≤ 1.5 x upper limit of normal (ULN) or ≤ 3 x ULN for patients with Gilbert's disease obtained ≤ 15 days prior to registration\n* Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤ 2.5 x ULN obtained ≤ 15 days prior to registration\n* Glomerular filtration rate (GFR) or calculated creatinine clearance ≥ 30 ml/min as estimated using the Cockcroft-Gault formula or as measured by 24-hour urine collection obtained ≤ 15 days prior to registration\n* Provide written informed consent\n* Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)\n\nExclusion Criteria:\n\n* Pure verrucous carcinoma of the penis\n* Non-squamous malignancy of the penis\n* Squamous carcinoma of the urethra\n* Preexisting sensory or motor neuropathy ≥ grade 2\n* Active central nervous system (CNS) metastases. Exception: Treated CNS metastases are allowed if all of the following are true:\n\n * CNS metastases are clinically stable for ≥ 6 weeks prior to registration\n * If needed, steroid dose is stable and ≤ 20 mg/day of prednisone or equivalent for ≥ 2 weeks prior to registration\n * Baseline imaging shows no evidence of new or enlarged brain metastasis\n * No leptomeningeal disease\n* History of uncontrolled diabetes mellitus ≤ 3 months prior to registration NOTE: Uncontrolled diabetes is defined as hemoglobin A1c (HbA1c) ≥ 8.0% or HbA1c 7.0-7.9% with associated diabetes symptoms (polyuria or polydipsia) that are not otherwise explained\n* Failure to recover from any of the following therapies prior to registration:\n\n * Major surgery\n * Radiotherapy, chemotherapy, biologics, investigational agents, and/or antitumor treatment with immunotherapy\n* Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive\n* Uncontrolled intercurrent illness including, but not limited to:\n\n * Ongoing or active infection requiring systemic treatment\n * History of cerebral vascular event (stroke or transient ischemic attack)\n * Myocardial infarction or symptomatic congestive heart failure (New York Heart Association \\[NYHA\\] Class III-IV) ≤ 6 months prior to registration\n * Unstable angina pectoris\n * Cardiac arrhythmia\n * Or psychiatric illness/social situations that would limit compliance with study requirements (e.g., history of substance abuse)\n* Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm\n* Currently receiving systemic antimicrobial treatment for viral, bacterial or fungal infection. NOTE: Routine antimicrobial prophylaxis is allowed\n* Known active hepatitis B (e.g., hepatitis B surface antigen \\[HBsAg\\] reactive) or active hepatitis C (e.g., hepatitis C virus \\[HCV\\] ribonucleic acid (RNA) \\[qualitative\\] is detected)\n* Known active keratitis or corneal ulcerations. NOTE: Superficial punctate keratitis is allowed if the disorder is being adequately treated\n* Known hypersensitivity to enfortumab vedotin or to any excipient contained in the drug formulation of enfortumab vedotin (including histidine, trehalose dihydrate and polysorbate 20) OR subject has known hypersensitivity to biopharmaceutical produced in Chinese hamster ovary cells\n* Other active malignancy ≤ 2 years prior to registration. EXCEPTIONS: Locally curable cancers that have been apparently cured such as basal or squamous cell skin cancer, non-muscle-invasive bladder cancer, or carcinoma in situ of the breast or low risk Gleason 6 prostate cancer.\n* History of myocardial infarction ≤ 6 months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias\n* Patients who are sexually active and unwilling to use effective contraception (if they are not already surgically sterile)\n* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* Chemotherapy-naïve patients who are potentially curable (any T, N1 - N3, M0) in the absence of any condition that precludes cisplatin-based chemotherapy, such as low GFR, peripheral neuropathy, hearing impairment, or psychosocial considerations"}, 'identificationModule': {'nctId': 'NCT06104618', 'briefTitle': 'Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis', 'organization': {'class': 'OTHER', 'fullName': 'Mayo Clinic'}, 'officialTitle': 'Phase II Study of Enfortumab Vedotin Treatment for Metastatic Squamous Cell Carcinoma of the Penis', 'orgStudyIdInfo': {'id': 'MC200505'}, 'secondaryIdInfos': [{'id': 'NCI-2023-08624', 'type': 'REGISTRY', 'domain': 'CTRP (Clinical Trial Reporting Program)'}, {'id': '20-011329', 'type': 'OTHER', 'domain': 'Mayo Clinic Institutional Review Board'}, {'id': 'MC200505', 'type': 'OTHER', 'domain': 'Mayo Clinic in Rochester'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Treatment (Enfortumab vedotin)', 'description': 'Patients receive enfortumab vedotin IV over 30 minutes on days 1,8 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI throughout the study.', 'interventionNames': ['Drug: Enfortumab Vedotin', 'Procedure: Computed Tomography', 'Procedure: Magnetic Resonance Imaging']}], 'interventions': [{'name': 'Enfortumab Vedotin', 'type': 'DRUG', 'otherNames': ['AGS 22ME', 'AGS-22M6E', 'Anti-Nectin 4 ADC ASG-22CE', 'Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E', 'ASG-22CE', 'Enfortumab Vedotin-ejfv', 'Padcev'], 'description': 'Given IV', 'armGroupLabels': ['Treatment (Enfortumab vedotin)']}, {'name': 'Computed Tomography', 'type': 'PROCEDURE', 'otherNames': ['CAT', 'CAT Scan', 'Computed Axial Tomography', 'computerized axial tomography', 'Computerized Axial Tomorgraphy', 'computed axial tomogrpahy', 'Computerized Tomography', 'computerized tmography', 'Computerized Tomography (CT) scan', 'CT', 'CT Scan'], 'description': 'Undergo CT', 'armGroupLabels': ['Treatment (Enfortumab vedotin)']}, {'name': 'Magnetic Resonance Imaging', 'type': 'PROCEDURE', 'otherNames': ['MRI', 'Magnetic Resonance Imaging (MRI)', 'Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance', 'MR', 'MRI Scan', 'NMR Imaging', 'NMRI', 'nuclear magnetic resonance imaging', 'Nuclear Resonance Magnetic Imaging', 'structural MRI', 'sMRI'], 'description': 'Undergo MRI', 'armGroupLabels': ['Treatment (Enfortumab vedotin)']}]}, 'contactsLocationsModule': {'locations': [{'zip': '85054', 'city': 'Phoenix', 'state': 'Arizona', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Clinical Trials Referral Office', 'role': 'CONTACT', 'email': 'mayocliniccancerstudies@mayo.edu', 'phone': '855-776-0015'}, {'name': 'Cassandra N. Moore, M.D.', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Mayo Clinic Hospital in Arizona', 'geoPoint': {'lat': 33.44838, 'lon': -112.07404}}, {'zip': '32224-9980', 'city': 'Jacksonville', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Clinical Trials Referral Office', 'role': 'CONTACT', 'email': 'mayocliniccancerstudies@mayo.edu', 'phone': '855-776-0015'}, {'name': 'Winston W. Tan, M.D.', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Mayo Clinic in Florida', 'geoPoint': {'lat': 30.33218, 'lon': -81.65565}}, {'zip': '55905', 'city': 'Rochester', 'state': 'Minnesota', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Clinical Trials Referral Office', 'role': 'CONTACT', 'email': 'mayocliniccancerstudies@mayo.edu', 'phone': '855-776-0015'}, {'name': 'Lance C. Pagliaro, M.D.', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Mayo Clinic in Rochester', 'geoPoint': {'lat': 44.02163, 'lon': -92.4699}}], 'centralContacts': [{'name': 'Clinical Trials Referral Office', 'role': 'CONTACT', 'email': 'mayocliniccancerstudies@mayo.edu', 'phone': '855-776-0015'}], 'overallOfficials': [{'name': 'Lance C. Pagliaro, M.D.', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Mayo Clinic in Rochester'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Mayo Clinic', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}